ArticleERJ open research2025
Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although clinical trial evidence exists, there is limited awareness of the real-world effectiveness of mepolizumab in patients with severe asthma and blood eosinophil counts (BEC) ≥150-<300 cells·μL Methods: REALITI-A, an international, prospective, single-arm, observational cohort study enrolled patients with severe asthma initiating mepolizumab. Outcomes assessed over 2 years pre- Results: After 2 years of mepolizumab treatment, compared with pre-exposure, the proportion of patients with BEC ≥150-<300 cells·μL Conclusions: These real-world findings provide evidence for the 2-year sustained benefit following initiation of mepolizumab in patients with severe asthma who have poor disease control and BEC ≥150-<300 cells·μL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.